AAP
INMB icon

Arax Advisory Partners’s INmune Bio INMB Stock Holding History

Arax Advisory Partners’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75 Buy
+66
New +$94 ﹤0.01% 3633
2025
Q4 		– Sell
-490
Closed -$1.01K – 4300
2025
Q3 		$1.01K Buy
+490
New +$1.12K ﹤0.01% 3254

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arax Advisory Partners's INMB Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in INmune Bio (INMB) in Q1 2026: 66 shares worth $75. The stake represents ﹤0.01% of the portfolio and ranks #3633 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in INMB as recently as Q3 2025.

Arax Advisory Partners first reported a position in INMB in Q3 2025 and has held it in 2 quarters since. The position peaked at $1.01K in Q3 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Arax Advisory Partners held 66 shares of INmune Bio worth $75 as of Q1 2026.
  • INmune Bio was a new Arax Advisory Partners position in Q1 2026.
  • INmune Bio made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3633 holding.
  • Arax Advisory Partners first reported a position in INmune Bio in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's INmune Bio position peaked at $1.01K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.